Clinical Trial Update: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B [Phase 3]

View source ↗

Summary

A Phase 3 study of IB1001, a recombinant factor IX product, was terminated in previously treated pediatric subjects with Hemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• IB1001 (Recombinant Factor IX)

Snippet

Sponsor: Medexus Pharma, Inc. | Conditions: Hemophilia B | Phase 3 | Status: TERMINATED | Results posted: 2019-04-11